Article

The genetic response to short-term interventions affecting cardiovascular function: Rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study

Division of Endocrinology, Department of Medicine, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
American heart journal (Impact Factor: 4.56). 06/2008; 155(5):823-8. DOI: 10.1016/j.ahj.2008.01.019
Source: PubMed

ABSTRACT The etiology of cardiovascular disease (CVD) is multifactorial. Efforts to identify genes influencing CVD risk have met with limited success to date, likely because of the small effect sizes of common CVD risk alleles and the presence of gene by gene and gene by environment interactions.
The HAPI Heart Study was initiated in 2002 to measure the cardiovascular response to 4 short-term interventions affecting cardiovascular risk factors and to identify the genetic and environmental determinants of these responses. The measurements included blood pressure responses to the cold pressor stress test and to a high salt diet, triglyceride excursion in response to a high-fat challenge, and response in platelet aggregation to aspirin therapy.
The interventions were carried out in 868 relatively healthy Amish adults from large families. The heritabilities of selected response traits for each intervention ranged from 8% to 38%, suggesting that some of the variation associated with response to each intervention can be attributed to the additive effects of genes.
Identifying these response genes may identify new mechanisms influencing CVD and may lead to individualized preventive strategies and improved early detection of high-risk individuals.

Full-text

Available from: Evadnie Rampersaud, May 23, 2015
0 Followers
 · 
165 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose:Vascular endothelial growth factor receptor (VEGFR) kinases are important drug targets in oncology that affect function of systemic endothelial cells. To discover genetic markers that affect VEGFR inhibitor pharmacodynamics we performed a genome-wide association study of serum soluble vascular endothelial growth factor receptor-2 concentrations [sVEGFR2], a pharmacodynamic biomarker for VEGFR2 inhibitors. Experimental Design:We conducted a genome-wide association study (GWAS) of [sVEGFR2] in 736 healthy Old Order Amish volunteers. Gene variants identified from the GWAS were genotyped serially in a cohort of 128 advanced solid tumor patients with baseline [sVEGR2] measurements, and in 121 renal carcinoma patients with [sVEGFR2] measured before and during pazopanib therapy. Results:rs34231037 (C482R) in KDR, the gene encoding sVEGFR2 was found to be highly associated with [sVEGFR2], explaining 23% of the variance (p=2.7x10-37). Association of rs34231037 with [sVEGFR2] was replicated in 128 patients with cancer with comparable effect size (p = 0.025). Furthermore rs34231037 was a significant predictor of changes in [sVEGFR2] in response to pazopanib (p = 0.01). Conclusions: Our findings suggest that genome-wide analysis of phenotypes in healthy populations can expedite identification of candidate pharmacogenetic markers. Genotyping for germ-line variants in KDR may have clinical utility in identifying cancer patients with unusual sensitivity to effects of VEGFR2 kinase inhibitors.
    Clinical Cancer Research 11/2014; 21(2). DOI:10.1158/1078-0432.CCR-14-1683 · 8.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lipoprotein (a) [Lp(a)] is an independent risk factor for atherosclerosis-related events that is under strong genetic control (heritability=0.68-0.98). However, causal mutations and functional validation of biological pathways modulating Lp(a) metabolism are lacking. We performed a genome-wide association scan to identify genetic variants associated with Lp(a)-cholesterol levels in the Old Order Amish. We confirmed a previously known locus on chromosome 6q25-26 and found Lp(a) levels also to be significantly associated with a SNP near the APOA5-APOA4-APOC3-APOA1 gene cluster on chromosome 11q23 linked in the Amish to the APOC3 R19X null mutation. On 6q locus, we detected associations of Lp(a)-cholesterol with 118 common variants (P=5×10(-8) to 3.91×10(-19)) spanning a ∼5.3 Mb region that included the LPA gene. To further elucidate variation within LPA, we sequenced LPA and identified two variants most strongly associated with Lp(a)-cholesterol, rs3798220 (P=1.07×10(-14)) and rs10455872 (P=1.85×10(-12)). We also measured copy numbers of kringle IV-2 (KIV-2) in LPA using qPCR. KIV-2 numbers were significantly associated with Lp(a)-cholesterol (P=2.28×10(-9)). Conditional analyses revealed that rs3798220 and rs10455872 were associated with Lp(a)-cholesterol levels independent of each other and KIV-2 copy number. Furthermore, we determined for the first time that levels of LPA mRNA were higher in the carriers than noncarriers of rs10455872 (P=0.0001) and were not different between carriers and noncarriers of rs3798220. Protein levels of apo(a) were higher in the carriers than noncarriers of both rs10455872 and rs3798220. In summary, we identified multiple independent genetic determinants for Lp(a)-cholesterol. These findings provide new insights into Lp(a) regulation. © The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
    Human Molecular Genetics 01/2015; 24(8). DOI:10.1093/hmg/ddu731 · 6.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Se han publicado multitud de estudios sobre la relación entre el riesgo de enfermedad cardiovascular y diversos nutrientes, alimentos y patrones de alimentación. A pesar del concepto bien aceptado de que la dieta tiene una influencia significativa en el desarrollo y la prevención de la enfermedad cardiovascular, los alimentos considerados saludables o perjudiciales han variado con el paso de los años. Esta revisión tiene como objetivo resumir la evidencia científica existente sobre el efecto cardioprotector de los alimentos y nutrientes que se ha considerado saludables y el de aquellos a los que se ha atribuido un carácter no saludable en algún momento de la historia. Para este fin, se ha revisado la literatura científica reciente empleando las palabras clave foods y nutrients (p. ej., carne, omega-3) y términos relacionados con la enfermedad cardiovascular (p. ej., enfermedades cardiovasculares, ictus). Se ha hecho especial énfasis en los metanálisis y las revisiones Cochrane. En general, son escasos los estudios de intervención con un nivel de evidencia alto que respaldan los efectos beneficiosos de los alimentos saludables (como frutas y verduras), mientras que la evidencia que respalda los argumentos en contra de los alimentos considerados menos saludables (como las grasas saturadas) parece haberse debilitado con la evidencia más reciente. En resumen, la mayor parte de la evidencia que respalda los efectos beneficiosos y nocivos de alimentos y nutrientes se basa en estudios epidemiológicos observacionales. Los resultados de los ensayos clínicos aleatorizados revelan un cuadro más confuso, en el que la mayoría de los estudios muestran unos efectos muy pequeños en uno u otro sentido; la evidencia más sólida es la que procede de los patrones de alimentación. El conocimiento actual de la relación entre dieta y riesgo de enfermedad cardiovascular requiere unas recomendaciones más individualizadas, basadas en técnicas de genómica.
    Revista Espanola de Cardiologia 09/2014; 67(9). DOI:10.1016/j.rec.2014.05.003